Valuation: Xintela AB

Market Cap 201M 20.66M 18.11M 16.7M 15.63M 29.31M 1.95B 29.92M 77.65M 963M 77.57M 75.88M 3.34B P/E 2024
-4.83x
P/E 2025 -4.03x
Enterprise Value 197M 20.33M 17.82M 16.43M 15.38M 28.84M 1.92B 29.44M 76.41M 948M 76.33M 74.66M 3.29B EV / Sales 2024
40,571,997x
EV / Sales 2025 85,656,603x
Free-Float
32.14%
Yield 2024 *
-
Yield 2025 -
1 day+17.97%
1 week+23.28%
Current month+2.19%
1 month-3.32%
3 months-2.92%
6 months-13.38%
Current year-17.96%
1 week 0.18
Extreme 0.176
0.24
1 month 0.16
Extreme 0.161
0.25
Current year 0.16
Extreme 0.161
0.35
1 year 0.16
Extreme 0.161
0.53
3 years 0.16
Extreme 0.161
0.7
5 years 0.16
Extreme 0.161
2.68
10 years 0.16
Extreme 0.161
8.92
Manager TitleAgeSince
Chief Executive Officer 69 2009-03-31
Director of Finance/CFO 65 2012-12-31
Chief Tech/Sci/R&D Officer 55 2020-12-31
Director TitleAgeSince
Director/Board Member 69 2020-12-31
Chairman 69 2010-12-31
Director/Board Member 66 2021-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+17.97%+23.28%-45.18%-13.38% 20.66M
-0.48%+7.20%-5.65%+1.02% 46.2B
+2.19%+11.71%+393.31%+580.42% 38.71B
+2.53%+13.93%+21.38%-12.81% 31.9B
+1.65%+3.61%+16.04%+55.62% 31.12B
-4.16%-2.58%+8.94%+25.31% 23.77B
-0.32%+12.96% - - 16.2B
+1.37%+14.53%+69.64%+130.07% 15.05B
+1.00%+10.30%+13.31%+20.31% 13.74B
+3.63%+9.53%+103.97%+98.73% 13.42B
Average +2.54%+10.55%+63.97%+98.36% 23.01B
Weighted average by Cap. +0.76%+8.71%+88.73%+130.88%

Financials

2024 2025
Net sales 4.22 0.43 0.38 0.35 0.33 0.62 40.93 0.63 1.63 20.23 1.63 1.59 70.15 2.28 0.23 0.21 0.19 0.18 0.33 22.16 0.34 0.88 10.95 0.88 0.86 37.98
Net income -39.19M -4.03M -3.54M -3.26M -3.05M -5.72M -381M -5.84M -15.16M -188M -15.15M -14.82M -652M -48.56M -5M -4.38M -4.04M -3.78M -7.09M -472M -7.24M -18.79M -233M -18.77M -18.36M -808M
Net Debt -16.68M -1.72M -1.51M -1.39M -1.3M -2.44M -162M -2.49M -6.45M -80.05M -6.45M -6.31M -278M -3.21M -330K -290K -267K -250K -469K -31.15M -478K -1.24M -15.4M -1.24M -1.21M -53.39M
Logo Xintela AB
Xintela AB (Xintela) is a Sweden-based biomedical company engaged in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumors. In the field of regenerative medicine, the Company focuses on cartilage damage and osteoarthritis, and in the field of brain tumors, its focuses on the development of a treatment for glioblastoma, an aggressive tumor. The Company has developed therapeutic antibodies, which bind to cancer cells. It has also developed XINMARK, a marker technology which consists of specific proteins, which work as recognition flags on the surface of certain cells. The markers make it possible to identify and select certain types of stem cells which can develop into cartilage cells.
Employees
11
Date Price Change Volume
26-06-26 SEK 0.2330 +17.97% 645,249
26-06-25 SEK 0.1975 +9.72% 305,036
26-06-24 SEK 0.1800 -6.25% 494,759
26-06-23 SEK 0.1920 -1.54% 35,726
  1. Stock Market
  2. Stocks
  3. XINT Stock